Tirofiban-d9
Tirofiban-d9 is deuterium labeled Tirofiban.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1332075-40-7
- Formule: C22H27D9N2O5S
- Masse moléculaire:449.65
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1332075-40-7
-
Unlabeled Cas 144494-65-5
-
Masse moléculaire 449.65
-
Formule C22H27D9N2O5S
-
SMILES
O=S(N[C@H](C(O)=O)CC1=CC=C(C=C1)OCCCCC2CCNCC2)(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O
-
Synonyms
L700462-d9; MK383-d9
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [Content Brief]
[3]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [Content Brief]
[4]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [Content Brief]
[5]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [Content Brief]
[6]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz